Literature DB >> 30319927

The Life Cycle of the Uterine Fibroid Myocyte.

Gordon P Flake1, Alicia B Moore2, Deloris Sutton1, Norris Flagler1, Natasha Clayton1, Grace E Kissling3, Benita Wicker Hall1, John Horton1, David Walmer4, Stanley J Robboy4, Darlene Dixon2.   

Abstract

PURPOSE OF REVIEW: Uterine fibroids are common benign tumors of women in the USA and worldwide, yet the biological nature and pathogenesis of these tumors remain largely unknown. This review presents our view of the stages in the life cycle of a subset of uterine fibroid myocytes, introduces hypothetical concepts and morphological data to explain these changes, and relates these changes in individual myocytes to the phases of fibroid tumor development. RECENT
FINDINGS: The observations gained from light and electron microscopic, immunohistochemical, and morphometric studies in our laboratory have led to the hypothesis that fibroid changes over time may relate to the excessive production of collagen by phenotypically transformed myocytes. This accumulation of collagen results in decreased microvessel density, followed by myocyte injury and atrophy, with eventual senescence and involution through ischemic cellular degeneration and inanition.
SUMMARY: Uterine leiomyomas, or fibroids, are characterized by two histologic features-proliferation of myocytes and production of an extracellular collagenous matrix. In the larger tumors, the collagenous matrix is often abundant. Within those regions in which the accumulating collagen is excessive, the myocytes are progressively separated from their blood supply, resulting in myocyte atrophy and eventually cell death. It is within these hypocellular, hyalinized areas that the complete lifecycle of the fibroid myocyte is realized. It begins with the phenotypic transformation of a contractile cell to one characterized by proliferation and collagen synthesis, progresses through an intermediate stage of atrophy related to interstitial ischemia, and eventuates in cell death due to inanition. Lastly, resorption of inanotic cells appears to occur by a non-phagocytic, presumably enzymatic process of degradation and recycling that we refer to as reclamation.

Entities:  

Keywords:  Myocyte; Uterine fibroids; Uterine leiomyomas

Year:  2018        PMID: 30319927      PMCID: PMC6183063          DOI: 10.1007/s13669-018-0241-7

Source DB:  PubMed          Journal:  Curr Obstet Gynecol Rep        ISSN: 2161-3303


  10 in total

Review 1.  Regulation of differentiation of vascular smooth muscle cells.

Authors:  G K Owens
Journal:  Physiol Rev       Date:  1995-07       Impact factor: 37.312

2.  Mechanisms of stenosis after arterial injury.

Authors:  A W Clowes; M A Reidy; M M Clowes
Journal:  Lab Invest       Date:  1983-08       Impact factor: 5.662

3.  Association of race, age and body mass index with gross pathology of uterine fibroids.

Authors:  Alicia B Moore; Gordon P Flake; Carol D Swartz; Glenn Heartwell; Deborah Cousins; Joseph K Haseman; Grace E Kissling; Mary K Sidawy; Darlene Dixon
Journal:  J Reprod Med       Date:  2008-02       Impact factor: 0.142

4.  Growth of uterine leiomyomata among premenopausal black and white women.

Authors:  Shyamal D Peddada; Shannon K Laughlin; Kelly Miner; Jean-Philippe Guyon; Karen Haneke; Heather L Vahdat; Richard C Semelka; Ania Kowalik; Diane Armao; Barbara Davis; Donna Day Baird
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-01       Impact factor: 11.205

5.  High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence.

Authors:  Donna Day Baird; David B Dunson; Michael C Hill; Deborah Cousins; Joel M Schectman
Journal:  Am J Obstet Gynecol       Date:  2003-01       Impact factor: 8.661

6.  Cell proliferation and apoptosis in human uterine leiomyomas and myometria.

Authors:  Darlene Dixon; Gordon P Flake; Alicia B Moore; Hong He; Joseph K Haseman; John I Risinger; Johnathan M Lancaster; Andrew Berchuck; J Carl Barrett; Stanley J Robboy
Journal:  Virchows Arch       Date:  2002-03-23       Impact factor: 4.064

7.  New concepts in the treatment of uterine leiomyomas.

Authors:  E A Stewart; R A Nowak
Journal:  Obstet Gynecol       Date:  1998-10       Impact factor: 7.661

Review 8.  Etiology and pathogenesis of uterine leiomyomas: a review.

Authors:  Gordon P Flake; Janet Andersen; Darlene Dixon
Journal:  Environ Health Perspect       Date:  2003-06       Impact factor: 9.031

9.  The natural history of uterine leiomyomas: morphometric concordance with concepts of interstitial ischemia and inanosis.

Authors:  Gordon P Flake; Alicia B Moore; Norris Flagler; Benita Wicker; Natasha Clayton; Grace E Kissling; Stanley J Robboy; Darlene Dixon
Journal:  Obstet Gynecol Int       Date:  2013-09-30

10.  The natural history of uterine leiomyomas: light and electron microscopic studies of fibroid phases, interstitial ischemia, inanosis, and reclamation.

Authors:  Gordon P Flake; Alicia B Moore; Deloris Sutton; Grace E Kissling; John Horton; Benita Wicker; David Walmer; Stanley J Robboy; Darlene Dixon
Journal:  Obstet Gynecol Int       Date:  2013-11-21
  10 in total
  3 in total

1.  Summary of the Proceedings of the Basic Science of Uterine Fibroids Meeting: New Developments February 28, 2020.

Authors:  Phyllis C Leppert; Ayman Al-Hendy; Donna D Baird; Serdar Bulun; William Catherino; Darlene Dixon; Merrick Ducharme; Quaker E Harmon; Friederike L Jayes; Emmanuel Paul; Aymara Mas Perucho; James Segars; Carlos Simón; Elizabeth A Stewart; Jose Teixeira; Andrea Tinelli; Daniel Tschumperlin; Ami R Zota
Journal:  F S Sci       Date:  2020-11-07

2.  Short-term tetrabromobisphenol A exposure promotes fibrosis of human uterine fibroid cells in a 3D culture system through TGF-beta signaling.

Authors:  Jingli Liu; Linda Yu; Lysandra Castro; Yitang Yan; Natasha P Clayton; Pierre Bushel; Norris D Flagler; Erica Scappini; Darlene Dixon
Journal:  FASEB J       Date:  2022-02       Impact factor: 5.834

Review 3.  Comprehensive Review of Uterine Fibroids: Developmental Origin, Pathogenesis, and Treatment.

Authors:  Qiwei Yang; Michal Ciebiera; Maria Victoria Bariani; Mohamed Ali; Hoda Elkafas; Thomas G Boyer; Ayman Al-Hendy
Journal:  Endocr Rev       Date:  2022-07-13       Impact factor: 25.261

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.